ISPOR - EE506 Budget Impact and Cost-Utility Analysis of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Renal Cell Cancer (aRCC) in Costa Rica

Full Text

EE506 Budget Impact and Cost-Utility Analysis of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Renal Cell Cancer (aRCC) in Costa Rica

Abstract

Authors

V Cervera F Ruiz A Vieto E Mejicanos

Back to Volume 27, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now